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Accumulating evidence suggests that in the vertebrate embryo, acquisition of arterial and venous identity is established early by genetic
mechanisms, including those regulated by vascular endothelial growth factor (VEGF) and Notch signaling. However, although the COUP-TFII
nuclear receptor has recently been shown to regulate vein identity, very little is known about the molecular mechanisms of transcriptional
regulation in arterial specification. Here, we show that mouse embryos compound mutant for Foxc1 and Foxc2, two closely related Fox
transcription factors, exhibit arteriovenous malformations and lack of induction of arterial markers whereas venous markers such as COUP-TFII
are normally expressed, suggesting that mutant endothelial cells fail to acquire an arterial fate. Notably, consistent with this observation,
overexpression of Foxc genes in vitro induces expression of arterial markers such as Notch1 and its ligand Delta-like 4 (Dll4), and Foxc1 and
Foxc2 directly activate the Dll4 promoter via a Foxc-binding site. Moreover, compound Foxc mutants show a defect in sprouting of lymphatic
endothelial cells from veins in early lymphatic development, due to reduced expression of VEGF-C. Taken together, our results demonstrate that
Foxc transcription factors are novel regulators of arterial cell specification upstream of Notch signaling and lymphatic sprouting during embryonic
development.
© 2006 Elsevier Inc. All rights reserved.Keywords: Vascular development; Arterial-venous specification; Lymphatic development; Notch; Forkhead; VEGFIntroduction
Blood vessels in the embryo and extraembryonic membranes
first form as a primitive vascular network by differentiation and
proliferation of endothelial cell precursors, angioblasts (vascu-
logenesis). The vessels subsequently remodel by the process of
angiogenesis to form the small and large vessels of the mature
vasculature. These complex processes depend on the precisely
coordinated and sequential actions of several angiogenic growth
factors such as the vascular endothelial growth factor (VEGF)
(Gale and Yancopoulos, 1999; Rossant and Howard, 2002).
Whereas anatomical differences between arteries and veins have
long been understood, recent evidence demonstrates that in the
vertebrate embryo, angioblasts become committed to arterial or⁎ Corresponding author. Fax: +1 615 936 1872.
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doi:10.1016/j.ydbio.2006.03.035venous lineages before circulation begins (Lawson et al., 2001,
2002, 2003; Mukouyama et al., 2002; Zhong et al., 2001). The
Notch pathway induces arterial specification, and the VEGF
pathway functions upstream of the Notch pathway in this
process (Alva and Iruela-Arispe, 2004; Lawson et al., 2002,
2003; Mukouyama et al., 2002; Shawber et al., 2003).
Consistent with this idea, vascular expression of Notch pathway
receptors and ligands has been shown to be restricted to arterial
endothelial cells in the early mouse and zebrafish embryo
(Lawson and Weinstein, 2002; Shutter et al., 2000; Uyttendaele
et al., 2001; Villa et al., 2001). On the other hand, a recent study
demonstrates that the COUP-TFII transcription factor expressed
in venous endothelium regulates a venous cell fate by repressing
Notch signaling (You et al., 2005). Although ephrinB2 and
EphB4 are expressed in arteries and veins, respectively, genetic
studies suggest that the ephrin/Eph pathway is not required for
the initial specification or determination of arterial-venous cell
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mouse and zebrafish embryos mutant for Notch signaling genes,
including the Delta-like 4 (Dll4) ligand and the downstream
targets Hey1/Hey2, fail to express arterial markers such as
ephrinB2 in endothelial cells and these mouse mutants show
severe vascular remodeling defects (Duarte et al., 2004; Fischer
et al., 2004; Kokubo et al., 2005; Krebs et al., 2004; Lawson et
al., 2001). Moreover, mutant embryos for Notch signaling genes
such as Dll4 result in the formation of arteriovenous
malformations (AVMs), the fusion of arteries and veins without
an intervening capillary bed (Duarte et al., 2004; Kokubo et al.,
2005; Krebs et al., 2004; Lawson et al., 2001, 2002; Zhong et
al., 2001). After the differentiation of endothelial cells into
veins, they subsequently sprout to form lymphatic vasculature
in the embryo (Hong et al., 2004; Oliver, 2004). However, the
cellular and molecular mechanisms governing these complex
processes still remain to be elucidated, and much more needs to
be discovered about how transcription factors respond to
extracellular signals and regulate gene expression at the onset of
arterial-venous specification and differentiation.
Foxc1 and Foxc2 (formerly Mf1 and Mfh1, respectively)
encode forkhead/Fox transcription factors (Carlsson and
Mahlapuu, 2002; Kaestner et al., 2000) with virtually identical
DNA-binding domains and very similar expression patterns in
various embryonic tissues. The two genes are first transcribed in
a dorsoventral gradient in the non-axial mesoderm with the
highest levels in the region closest to the neural tube (paraxial)
and the lowest levels ventrally (lateral) during gastrulation and
in numerous embryonic tissues, including the endothelial and
mesenchymal cells of blood vessels (Hiemisch et al., 1998; Iida
et al., 1997; Kume et al., 1998, 2000b, 2001; Sasaki and Hogan,
1993; Winnier et al., 1999). Since NMR structural analysis
suggests that the Foxc proteins have the same binding
specificity to a target sequence (van Dongen et al., 2000),
they are likely to regulate the same downstream target(s) where
they are coexpressed in the same cells. Although the consensus
DNA-binding sequence for Foxc1 has already been reported
using PCR-mediated DNA-binding site selection (Pierrou et al.,
1994), direct targets of Foxc in vivo remain largely unknown. It
has recently been shown that Foxc1 and Foxc2 can bind to the
enhancer of the T-box transcription factor Tbx1, regulating its
expression in the head mesenchyme (Yamagishi et al., 2003).
Although Foxc1 and Foxc2 are expressed in a variety of
embryonic tissues, this is the only known direct target of Foxc
during development.
Mice that are homozygous for either a spontaneous mutation
in Foxc1 (congenital hydrocephalus, Foxc1ch) or an engineered
null mutation (Foxc1lacZ) die both prenatally and perinatally
with identical phenotypes (Kume et al., 1998). These include
hemorrhagic hydrocephalus and multiple skeletal, ocular,
genitourinary, and cardiovascular defects, including the inter-
ruption or coarctation of the aortic arch, ventricular septal
defects (VSD), and aortic and pulmonary valve dysplasia
(Kidson et al., 1999; Kume et al., 1998, 2000b, 2001; Smith et
al., 2000; Winnier et al., 1999). Foxc2 null mutants die pre- and
perinatally with skeletal, genitourinary, and cardiovascular
defects similar to those seen in Foxc1 homozygous mutants(Iida et al., 1997; Kume et al., 2000b, 2001; Winnier et al.,
1997), suggesting the functional interaction between the two
genes. Surprisingly, the majority of compound heterozygotes
die soon after birth with a similar spectrum of cardiovascular,
genitourinary, and eye abnormalities as those seen in each single
homozygous null mutant (Kume et al., 2000b, 2001; Smith et
al., 2000; Winnier et al., 1999). These data suggest that they
functionally overlap in vivo. Moreover, compound homozy-
gous and hetero/homozygous embryos die in utero with a
phenotype that is much more severe than that of a single
homozygote and a compound heterozygote in a dose-dependent
manner (Kume et al., 2001). For example, most blood vessels
including the yolk sac vasculature in compound homozygous
mutants are disorganized plexi that have undergone very little
remodeling, compared to the wild type. Compound Foxc1+/−;
Foxc2−/− mutant embryos also have less severe but extensive
defects in the morphology and remodeling of the blood vessels
in the head and branchial arches. However, the molecular
mechanisms underlying the overlapping role of Foxc in vascular
development is still poorly understood.
A role for Foxc2 in lymphatic development is suggested by
the fact that humans and mice heterozygous for FOXC2/Foxc2
have lymphedema (Fang et al., 2000; Kriederman et al., 2003).
Recent studies have demonstrated that Foxc2 is expressed
lymphatic vessels in the developing embryos as well as in the
adult (Dagenais et al., 2004; Petrova et al., 2004), and that Foxc2
homozygous mice show agenesis of lymphatic valves and
increased pericyte investment of lymphatic vessels (Petrova et
al., 2004). We show here that compound Foxc1+/−; Foxc2−/−
mutants exhibit defects in the early sprouting and formation of
lymphatic vessels. Most importantly, compound Foxc1; Foxc2
homozygotes have AVMs and their endothelial cells fail to
express arterial markers including Dll4, consistent with our
finding that Foxc can directly transactivate the Dll4 promoter in
vitro. Taken together, we propose that the Foxc genes are
important new components of the genetic cascade regulating
arterial specification upstream of Notch signaling and lymphatic
sprouting during vascular development.
Materials and methods
Breeding mutant mice and genotyping
Mice heterozygous for the null mutations, Foxc1 and Foxc2, were
maintained by interbreeding and genotyped, and compound mutant embryos
were obtained by interbreeding compound Foxc1; Foxc2 heterozygotes as
described (Kume et al., 2001). At least two embryos of each genotype were
analyzed to determine expression patterns of marker genes. The number of the
somites was counted for staging wild-type and compound mutant embryos to
confirm no developmental delay in compound mutants. Since compound
homozygotes do not have the somites (Kume et al., 2001), their embryonic
stages were determined by comparing the body length of wild-type and
compound homozygous embryos.
Histological analysis
Histological analysis including H/E staining and section in situ hybridization
was performed as described (Kume et al., 1998, 2001, 2000a,b). For
immunohistochemical analysis, embryos were fixed with 4% paraformaldehye
in PBS, dehydrated, embedded in paraffin with standard procedures, and then
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sections was performed by heat treatment for 30 min in antigen retrieval reagent
Retrievit 6 (InnoGenex) for Prox1 antibody or by incubation with 0.025%
trypsin for 8 min at 37°C for PECAM-1, COUP-TFII, and EphB4 antibodies.
The sections were blocked for 20 min in PowerBlock (BioGenex) followed by
incubation with primary antibodies. The primary antibodies used were rat anti-
mouse CD31 (PECAM-1) (Pharmingen), goat anti-mouse EphB4 (R&D
System), mouse anti-human COUP-TFII (R&D System), rabbit anti-mouse
Lyve1 (Abcam), and rabbit anti-mouse Prox1 (Covance). After washing 3 times
for 10 min in PBS/0.05% Tween 20 (PBST), the sections were incubated with
secondary antibodies. The secondary antibodies used were Alexa 488 donkey
anti-goat IgG (Molecular Probes) for EphB4, Alexa 488 goat anti-mouse IgG
(Molecular Probes) for COUP-TFII, Alexa 488 donkey anti-rabbit IgG
(Molecular Probes) for Lyve1, and Cy-3 donkey anti-rabbit IgG (Jackson
ImmunoResearch Laboratories) for Prox1. For double immunofluorescence to
define endothelial cells, PECAM-1 was detected using either Alexa 568 goat
anti-rat IgG (Molecular Probes) for PECAM-1/COUP-TFII or rabbit anti-rat IgG
(Vector Laboratories) and Cy-3 donkey anti-rabbit IgG (Jackson ImmunoR-
esearch Laboratories) for PECAM-1/EphB4. Following extensive washes for
3 × 10 min in PBST, the sections were mounted with anti-fading agent Gel/
Mount (Biomeda).
Cell lines
COS-7 and 10T1/2 cells were purchased from American Type Culture
Collection (ATCC) and cultured according to the manufacturer's protocol.
Mouse embryonic endothelial cells (MEECs) were cultured as previously
described (Goumans et al., 2002).
RNA extraction and semi-quantitative RT-PCR analysis
Total RNA was isolated from MEECs or 10T1/2 cells using Trizol (BD
Biosciences) after 24 h of transfection with expression vectors and subjected to
semi-quantitative RT-PCR using AmpliTaq Gold (Applied Biosystems). The
cycle number for each primer set was determined within the linear range of
amplification of target cDNA (25 to 32 cycles). Primers used for RT-PCRwere as
follows: Gapdh, 5′-ACATCAAGAAGGTAGTGAAGCTGGC-3′ and 5′-
TTCAAGAGATTAGGGCTCCCTAGG-3′; Flk1, 5′-CCTACCCCACACAT-
TACATGG-3′ and 5′-TTTTCCTGGGCACCTTCTATT-3′; Notch1, 5′-CCAG-
CATGGCCAGCTCTGG-3′ and 5′-CATCCAGATCTGTGGCCCTGTT-3′;
Notch4, 5′-ACCCTGCTCCAATGGAGGAT-3′ and 5′-AGAACCTCCGATT-
CACACTCC-3′; Dll4, 5′-CGAGAGCAGGGAAGCCATGA-3′ and 5′-
CCTGCCTTATACCTCTGTGG-3′; Hey2, 5′-GTGGGGAGCGAGAACAAT-
TACCCTGG-3′ and 5′-TGCTGAGATGAGAGACAAGGCGCACG-3′;
ephrinB2, 5′-CTGTGCCAGACCAGACCAAGA-3′ and 5′-CAGCA-
GAACTTGCATCTTGTC-3′; EphB4, 5′-CAGGTGGTCAGCGCTCTGGAC-
3′ and 5′-ATCTGCCACGGTGGTGAGTCC-3′; PECAM-1, 5′-GACCCAG-
CAACATTCACAGAT-3′ and 5′-TCTTTCACAGAGCACCGAAGT-3′; Tie2,
5′-CGGCCAGGTACATAGGAGGAA-3, and 5-CCCCCACTTCTGAGCTT-
CAC-3′, Flt4, 5′-CGAGACTGGAAGGAGGTGAC-3′ and 5′-GTACGTG-
TAGTTGTCCGCCC-3′; COUP-TFII, 5′-AAGCTGTACAGAGAGGCAGGA-3′
and 5′-AGAGCTTTCCGAACCGTGTT-3′; Foxc1, 5′-GCGGAAATTG TAG-
GAGTTCCCTAG-3′ and 5′-TTTGGCATCTGGCTCACAGG-3′; Foxc2, 5′-
ACGAGTGCGGATTTGTAACCAG-3′ and 5′-GTGTTTTTGGAATACCCCA-
GATGG-3′.
Electrophoretic mobility shift assay (EMSA)
Foxc1 and Foxc2 proteins were synthesized using TNT-coupled reticulocyte
lysate system (Promega). Oligonucleotide probes were generated by annealing
complementary deoxyoligonucleotides at 85°C, end-labeled with [γ-32P] ATP
using T4 polynucleotide kinase, and were purified using Sephadex G-50
columns (Roche). For competition studies, the excess cold DNA fragments were
added and incubated for 15 min at RT before adding the DNA probe. Binding
reaction was performed at 25°C for 20 min in 20 μl of the slurry containing 2 μl
of in vitro translation product, 1 μg of poly (dI–dC), and typically 0.1 ng probe
(10,000 cpm, Cerenkov) in 20 mM HEPES, pH 7.9; 50 mM KCl; 2 mMMgCl2;0.5 mM EDTA; 10% glycerol; 0.1 mg/ml BSA; 2 mMDTT; 0.5 mM PMSF. The
samples were run on 6% polyacrylamide gel containing 1% Ficoll 400 and 5%
glycerol in Tris–glycine buffer (25 mM Tris, 190 mM glycine, 1 mM EDTA) at
10 V/cm at 4°C for 110 min. Gels were vacuum dried and subjected to
autoradiography. Deoxyoligonucleotides used for the FBE in the Dll4 promoter
were 5′-TTGTAAAATCGATTTATTGACCGGCAGGTGCGAGC-3′ and 5′-
GCTCGCACCTGCCGGTCAATAAATCGATTTTACAA-3′.
Plasmid constructs
A 3.7-kb fragment of the mouse Dll4 promoter (−3631/+76; XhoI/XhoI
fragment) isolated from a mouse 129SV genomic BAC library (BACPAC
Resources) was subcloned into the XhoI site of pGL3Basic (Promega) (pDll4-
3.7k-Luc). pDll4-3.7kmut-Luc was generated to mutate the FBE (ATTTATT-
GAC) to AAGCTTGAC using QuikChange site-directed Mutagenesis Kit
(Staratagene). A 2.1-kb region (−2028/+76; EcoRV/XhoI fragment) was
subcloned into SmaI/XhoI sites of pGL3Basic (pDll4-2.1k-Luc).
Luciferase reporter assay
COS-7 cells were transfected with 400 ng of expression vectors along with
100 ng of reporter constructs and 1 ng of pRL-SV40 Renilla using
Lipofectamine 2000 (Invitrogen). The total amount of expression plasmid
transfected per well was kept constant by addition of varying amounts of
pcDNA3.0 (Invitrogen). Luciferase assays were performed using Dual-
Luciferase Reporter Assay System (Promega) at 48 h after transfection as
described (Fujita et al., 2006). Each transfection was performed in triplicate and
replicated three times.
Statistics
Student's t test was performed to compare the average of two groups. A
value of P < 0.05 was considered statistically significant.Results
Compound Foxc1; Foxc2 mutant embryos have arteriovenous
malformations resulting from vascular fusions
It has previously shown that Foxc1 and Foxc2 are transcribed
in blood vessels of the embryo, and that compound Foxc1;
Foxc2 mutant embryos have abnormalities in cardiovascular
development (Kume et al., 2001; Winnier et al., 1999). In
particular, compound homozygous and hetero/homozygous
mutant embryos exhibit severe vascular defects in branching
morphogenesis and vessel remodeling in the yolk sac and
embryo proper (Kume et al., 2001). Whereas either the majority
of compound heterozygotes or all of each single homozygous
mutants die prenatally (from around embryonic day E14.5) or
soon after birth with a similar spectrum of cardiovascular
abnormalities such as the interruption of the aortic arch, a small
population of compound heterozygotes survive until adulthood
and are fertile. Compound Foxc1+/−; Foxc2−/−; and Foxc1−/−;
Foxc2+/− mutants can survive until E12.0–12.5, whereas
compound homozygous mutants die around E9.5. Although
these results suggest that Foxc1 and Foxc2 functionally overlap
and are required for embryonic development in a dose-
dependent manner, the precise mechanisms of the cooperative
role of Foxc1 and Foxc2 in vascular development, including
the identification of their direct targets, have not yet been
studied. Here, we found that at E8.25, when both circulation
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aorta and cardinal vein in compound homozygotes were fused
together (Fig. 1C). In addition, significantly enlarged blood
vessels possibly due to vascular fusions were observed in
compound homozygotes at E9.0 (Figs. 2B, D, F, H, J, L, N,
P, R, T, V, and X). Moreover, some compound Foxc1+/−;
Foxc2−/− mutants (2/8) had similar but less severe vascular
shunts at E9.0 (Fig. 1F) indicating incomplete penetrance,
whereas compound Foxc1−/−; Foxc2+/− mutants (0/8), as
well as single mutants (0/10) and compound heterozygotes (0/
9), showed no vascular fusions (data not shown). These
AVMs were frequently seen between the dorsal aorta and the
anterior cardinal vein at the level of the aortic sac. These data
suggest that the effects of the two Foxc genes on vascular
development are dose-dependent. It is suggested that AVMs
result from the defective separation of uncommitted angio-
blasts as arteries and veins during migration and/or formation
of blood vessels (Lawson and Weinstein, 2002). Importantly,
in addition to the failure of blood vessels to remodel during
development, similar AVMs have been observed in mouse and
zebrafish embryos mutant for Notch signaling genes such as
Dll4 (Duarte et al., 2004; Krebs et al., 2004; Lawson et al.,
2001), indicating that impaired arterial specification/differen-
tiation commonly leads to AVMs.
Compound Foxc1; Foxc2 homozygous null mutants
exhibit lack of induction of arterial markers
We next examined the expression patterns of vascular
markers, including Notch signaling genes in compound
homozygotes (Fig. 2). A pan-endothelial marker, Flk1 (also
known as VEGFR-2), was expressed in endothelial cells of
compound homozygotes (Fig. 2B), indicating that mesodermal
cells were normally specified to endothelial cells in compound
homozygotes. Intriguingly, transcripts for the arterial markers,
Notch1, Notch4, Dll4, Jagged1, Hey2, and ephrinB2, were allFig. 1. Arteriovenous malformations (AVMs) in compound Foxc1; Foxc2 muta
homozygous embryos at the level of the heart tube at E8.25. Serial sections (B, C) r
arrow) of blood vessels (C) compared with the dorsal aorta (da) and cardinal vein (c
Foxc1+/−; Foxc2−/− mutants at the level of the heart at E9.0. Serial sections (E, F) r
shunt (white arrow) between the dorsal aorta and anterior cardinal vein (F). g, gut;lost or reduced in endothelial cells of compound homozygotes
(Figs. 2D, F, H, J, L, and N). These data suggest that arterial
specification is impaired in compound homozygotes.
The VEGF pathway plays a crucial role in inducing arterial
specification upstream of Notch signaling (Lawson et al., 2002;
Mukouyama et al., 2002; Visconti et al., 2002). Neuropilin-1 is
a coreceptor for VEGF receptors and is expressed in arterial
endothelial cells (Moyon et al., 2001). In compound homo-
zygotes, Neuropilin-1 expression was significantly reduced
(Fig. 2P). By contrast, whereas VEGF is normally expressed
throughout the mouse embryo with highest levels in the gut
endoderm at E8.25 (Dumont et al., 1995), in compound
homozygotes VEGF expression was upregulated in the paraxial
mesoderm, neural tube, and endoderm as early as E8.25 (Fig.
2R and data not shown). Similar upregulation of VEGF,
possibly because of hypoxia caused by cardiovascular defects,
is observed in Mef2c mutant embryos at E9.5, but not at E8.25
when circulation is under way (Bi et al., 1999). This suggests
that the upregulation of VEGF in compound Foxc mutants is
unlikely to result from hypoxia. Because both Foxc1 and Foxc2
are normally expressed in the dorsal aorta and cardinal vein
(Supplementary Fig. 1), we also examined the expression of
venous markers in compound homozygotes. Interestingly,
compared to the wild type (Figs. 2S and U), COUP-TFII and
EphB4 proteins were similarly detected in endothelial cells of
compound homozygotes (Figs. 2T and V), suggesting proper
processes of venous specification/differentiation. This is
consistent with recent evidence that endothelial cells of Dll4
mutant embryos express EphB4 (Duarte et al., 2004), and it is
possible that COUP-TFII counteracts Foxc to repress Notch
signaling in veins (You et al., 2005). The expression of the
lymphatic vessel endothelial hyaluronan receptor 1 (Lyve1)
(Banerji et al., 1999) in the anterior cardinal vein at E9.0–9.5 is
thought to indicate that venous endothelial cells are already
competent to respond to a lymphatic-inducing signal (Oliver,
2004). The observation that Lyve1 protein was detected innt embryos. (A–C) PECAM-1 immunostaining of wild-type and compound
eveal that the compound homozygote has an AVM caused by the fusion (white
v) in the wild type (A). (D–F) Transverse sections of wild-type and compound
eveal that the compound Foxc1+/−; Foxc2−/− mutant embryo shows a vascular
nt, neural tube. Scale bars, 100 μm.
Fig. 2. Failure of induction of arterial markers in compound Foxc1; Foxc2 homozygotes. (A–R) Section in situ hybridization at E9.0 at the level of the heart. Sections
are counterstained with hematoxylin, and positive signals are shown in brown/red. In the wild type, Notch1, Notch4, Dll4, Jagged1,Hey2, ephrinB2, and Neuropilin-1
are expressed in arteries (black arrows) but not in veins (black arrowheads) (C, E, G, I, K, M, and O). In compound homozygous mutant embryos, none of these arterial
markers are induced in endothelial cells (white arrows) (D, F, H, J, L, N, and P). Expression of VEGF is upregulated in the compound homozygote (R) compared with
the wild type (Q). (S–V) Immunohistochemical analysis at E9.0 to detect expression of venous markers. In the wild type, COUP-TFII and EphB4 are expressed in
veins (white arrowheads) but not in arteries (white arrows) (S and U). Similarly, PECAM-1+ endothelial cells (red arrows) of compound homozygotes express both
COUP-TFII (T) and EphB4 (V). (W, X) Immunohistochemical analysis at E9.0 to detect Lyve1 in the cardinal vein. Similar to the wild type (W), Lyve1 protein is
localized in endothelial cells of the compound homozygote (red arrow) (X). nt, neural tube. Scale bar, 100 μm.
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reinforces their acquirement of a venous fate.
Taken together, these results indicate that endothelial cells of
compound Foxc mutants exhibit a failure of arterial specifica-
tion leading to AVMs as well as vascular remodeling defects
and that this phenotype is not due to cardiac defects (Kume et
al., 2001), but primary to vascular abnormalities, consistent
with recent evidence that the initiation of arterial marker
expression is genetically predetermined and independent of
blood flow (Le Noble et al., 2004; Moyon et al., 2001).Compound Foxc1+/−; Foxc2−/− mutants exhibit defective
formation of lymphatic vessels
Recent studies have shown that single Foxc2 homozygous
mutant embryos have normal development of the initial
budding of lymphatic primordia and subsequent formation of
lymphatic sacs at E12.5 (Dagenais et al., 2004; Petrova et al.,
2004), although these mutants exhibit defective lymphatic
valves and abnormal pericyte investment of lymphatic vessels
in late development of the lymphatic vasculature (Petrova et al.,
463S. Seo et al. / Developmental Biology 294 (2006) 458–4702004). In agreement with the previous report (Dagenais et al.,
2004), we observed that Foxc2 expression is detected in the
mesenchymal cells surrounding the cardinal vein where the
specification and sprouting of lymphatic endothelial cells occur,
and, interestingly, its expression is overlapped with that of
Foxc1 (Figs. 3F and G). Furthermore, their expression domains
are localized in the mesenchyme expressing VEGF-C (Fig.
3H), which is required for the initial sprouting of lymphatic
vessels from the veins (Karkkainen et al., 2004). Therefore,
we tested whether compound Foxc mutants have normal
development of lymphatic vessels. Because compound
homozygotes cannot survive during lymphangiogenesis
(starting from E10.5), we examined the formation ofFig. 3. Defective lymphatic vessel development in compound Foxc1+/−; Foxc2−/− m
cell marker, Prox1, using transverse sections at the level of the heart at E10.5 (A, B
embryos (B) show the budding of lymphatic endothelial cells (arrows) from the cardin
wild type (A). (C, D) At E11.5, wild-type embryos (C) have well-formed lymph sacs
abnormal formation of the lymph sacs and the reduced sprouting of lymphatic endo
Quantitative analysis of Prox1-positive cells in wild-type and compound Foxc1+/−;
cells is significantly reduced in compound Foxc1+/−; Foxc2−/− mutants at both E1
genotype. (F–M) Section in situ hybridization at E10.5 (F–I) and E11.5 (J–M) at th
expression domains of Foxc1 (F) and Foxc2 (G) in the developing lymphatic region a
C expression is significantly reduced in compound Foxc1+/−; Foxc2−/− mutant em
contrast, expression levels of VEGFR-3 in lymphatic endothelial cells (arrowheads) ar
embryo (L). cv, cardinal vein; da, dorsal aorta. Scale bars, 50 μm (A–D) and 100 μlymphatic vessels in compound Foxc1+/−; Foxc2−/− mutant
embryos whose embryonic stages were matched with the
wild-type embryos at E10.5 and E11.5 (Fig. 3). At E10.5,
Prox1-positive cells have started sprouting from the cardinal
vein in the wild type (Fig. 3A). Interestingly, although
compound Foxc1+/−; Foxc2−/− embryos showed the bud-
ding of lymphatic endothelial cells from the cardinal vein
(Fig. 3B), our quantitative analysis revealed that the number
of Prox1-positive cells was significantly reduced compared to
the wild type (Fig. 3E). This observation was more evident at
E11.5 (Figs. 3D and E). Moreover, in contrast with wild-type
embryos, the abnormal formation of the lymph sacs was seen
in compound Foxc1+/−; Foxc2−/− mutants (Fig. 3D).utants. (A–D) Immunohistochemical analysis to detect a lymphatic endothelial
) and E11.5 (C, D). (A, B) Although compound Foxc1+/−; Foxc2−/− mutant
al vein, the number of Prox1-positive cells appears to be reduced compared to the
(asterisks) and the sprouting of lymphatic endothelial cells (arrows). By contrast,
thelial cells are observed in compound Foxc1+/−; Foxc2−/− mutants (D). (E)
Foxc2−/− mutant embryos at E10.5 and E11.5. The number of Prox1-positive
0.5 (P < 0.01) and E11.5 (P < 0.01). Data are collected from three embryos per
e level of the heart. In adjacent sections of wild-type embryo at E10.5 (F–H),
re partially overlapped with those of VEGF-C (H) as indicated by arrows. VEGF-
bryos at E10.5 (I) and E11.5 (K), compared to wild-type embryos (H, J). By
e normal in compound Foxc1+/−; Foxc2−/−mutant (M), compared to wild-type
m (I and M).
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VEGF-C, plays an important role in sprouting lymphatic vessels
to form the initial lymph sacs (Karkkainen et al., 2004), we next
examined their expression levels in compound Foxc1+/−;
Foxc2−/− mutants. Whereas VEGFR-3 expression was nor-
mally detected in lymphatic endothelial cells (Fig. 3M), levels
of VEGF-C transcripts were significantly reduced in compound
mutants (Figs. 3I and K), compared with the wild type (Figs. 3H
and J) at E10.5 and E11.5. In addition, in compound mutants, no
obvious reduction in cell proliferation was observed in Prox1-
positive lymphatic endothelial cells and surrounding mesen-
chymal cells, as well as other tissues at E10.5 and E11.5
(Supplementary Fig. 2). Taken together, these data suggest that
compound Foxc mutants have defects in the early processes of
lymphatic development.
Foxc1 and Foxc2 transcription factors induce expression of
arterial markers in vitro
To confirm defects in arterial specification/differentiation
observed in compound homozygotes (Fig. 2), we examined
whether Foxc1 and Foxc2 directly regulate transcripts of arterial
markers in vitro. As shown in Fig. 4, we found that transientFig. 4. Induction of arterial markers by overexpressing Foxc genes in vitro.
Foxc1 and Foxc2 significantly upregulate transcripts of arterial markers in
MEECs and 10T1/2 cells at 24 h after transfection. By contrast, transcripts of
pan-endothelial and venous markers are not changed by overexpressing Foxc.
Control indicates transfection of a mock expression vector. A representative
experiment is depicted (n = 4).overexpression of either Foxc1 or Foxc2 significantly upregu-
lates endogenous expression of Dll4, Notch1, Notch4, Hey2,
and ephrinB2 in mouse embryonic endothelial cells (MEECs)
(Goumans et al., 2002) as well as multipotent mesenchymal
10T1/2 cells, whereas expression of pan-endothelial markers
such as Flk1 was not changed. Moreover, no change in
expression of the venous markers, COUP-TFII and EphB4, was
observed by overexpression of Foxc genes in these cell lines.
Together, these data suggest that Foxc1 and Foxc2 are pivotal
transcriptional regulators acting upstream of Notch signaling in
arterial specification.
Foxc proteins bind and activate the Dll4 promoter through a
forkhead-binding element
It has recently been shown that Dll4 mutant embryos have
similar vascular abnormalities including AVMs (Duarte et al.,
2004; Gale et al., 2004; Krebs et al., 2004). Given that
expression of Dll4 is absent in endothelial cells of compound
Foxc homozygotes (Fig. 2H) and is upregulated by over-
expression of Foxc in vitro (Fig. 4), we sought to analyze the
effects of Foxc on the promoter activity of Dll4. In upstream
regions in the mouse and human Dll4 loci, there are two highly
conserved regions (HHRs), HHR1 and HHR2. Significantly, we
found that the HHR2 contains a putative Forkhead-binding
element (FBE), which fits the core consensus sequence
(Carlsson and Mahlapuu, 2002) (Fig. 5A). Using electropho-
retic mobility shift assay (EMSA), we found that Foxc1 and
Foxc2 proteins can directly bind to the FBE, whereas no DNA–
protein complex was detected with the mock expression vector
(Fig. 5B). It should be noted that the binding of Foxc proteins to
the FBE probe was strongly competed by the excess cold probe.
Next, in order to test whether Foxc can transactivate the mouse
Dll4 promoter by luciferase assay, we generated three reporter
plasmids, which contain the −3.7 kb promoter, −3.7 kb
promoter with a mutated FBE, and −2.1 kb promoter lacking
the HHR2 (Fig. 5C). We found that both Foxc1 and Foxc2
significantly activated the −3.7 kb promoter in a dose-
dependent manner (Fig. 5D). In addition, the induction of
luciferase activity by Foxc1 and Foxc2 using either the −2.1 kb
promoter or the −3.7 kb promoter with the mutated FBE was
greatly reduced in COS-7 cells and MEECs (Fig. 5D and data
not shown). These data strongly demonstrate that Foxc1 and
Foxc2 directly activate the Dll4 promoter via the FBE.
Consistent with the phenotype of compound Foxc1; Foxc2
mutants, these results indicate that the two Foxc genes act
upstream of Notch signaling regulating arterial cell identity.
Discussion
Our data demonstrate that Foxc1 and Foxc2 have dose-
dependent roles in arterial cell fate determination and that
complete absence of Foxc genes results in a failure in arterial
specification and malformations between arteries and veins.
Most significantly, we show in this study that the Notch ligand,
Dll4, is a downstream target of Foxc transcription factors.
Therefore, we propose that Foxc transcription factors directly
465S. Seo et al. / Developmental Biology 294 (2006) 458–470act upstream of Notch signaling in this process, an idea
consistent with recent studies that several mutant mice for
Notch signaling genes such asDll4, RBP-J, andHey1/Hey2 also
do not express arterial markers such as ephrinB2 (Duarte et al.,
2004; Fischer et al., 2004; Kokubo et al., 2004; Krebs et al.,
2004). Another intriguing finding is that compound Foxc
mutants have reduced expression of VEGF-C in the mesen-
chyme surrounding the cardinal vein, leading to impaired
sprouting of lymphatic vessels from the vein.
Foxc acts upstream of Notch signaling in arterial specification
Initial differentiation of endothelial cell lineage begins as a
subset of mesodermal cells. They are thought to differentiate
into bipotential progenitor cells, hemangioblasts (Huber et al.,
2004). These progenitor cells subsequently differentiate into
either endothelial or hematopoietic lineages. Endothelial
progenitors (angioblasts) become either arterial or venous
endothelial cells. Although it remains to be determined whether
endothelial cells in veins and arteries have distinct precursors,
molecular mechanisms underlying the development of arteries
and veins have recently been discovered. As described in the
Introduction, the VEGF signaling pathway activates Notch
signaling in endothelial cells, regulating arterial specification/
differentiation through the induction of artery-specific genes
(Lawson et al., 2002; Mukouyama et al., 2002; Stalmans et al.,
2002; Visconti et al., 2002). Because transcripts of Foxc1 and
Foxc2 are first detected in mesoderm during gastrulation, they
are likely to be expressed in arterial and venous precursors
before and at the time of cell fate specification. Our results
demonstrate that endothelial cells of compound homozygotes
fail to acquire an arterial cell fate although they appear to
differentiate from mesodermal cells and normally express pan-
endothelial markers such as Flk1 and PECAM-1 (Fig. 2B and
Kume et al., 2001). We cannot exclude the possibility that other
cell types of the surrounding tissues affect arterial specification
of endothelial cells in compound Foxc mutants since the Foxc
genes are broadly expressed in the mesoderm of the early
embryo. For example, although vascular smooth muscle
differentiation appears to be normal in compound homozygotes
(Kume et al., 2001), the problem of an earlier function for Foxc
genes in mesodermal patterning may be partly associated with
their vascular phenotype. Thus, in order to elucidate the precise
role of Foxc in vascular development, conditional ablation of
Foxc genes in an endothelial-specific manner needs to be
performed in the future.
The upregulation of VEGF in compound homozygotes (Fig.
1R) is quite intriguing although the cause of this phenotype
remains unclear. It has been shown that the VEGF concentration
gradient is spatially restricted (Ruhrberg et al., 2002), and that
VEGF expression in the somites of zebrafish embryos is vital
for the induction of arterial specification (Lawson et al., 2002).
The two Foxc genes are expressed in a dorsoventral gradient in
the non-axial mesoderm with the highest levels in paraxial
mesoderm (Kume et al., 2000b; Sasaki and Hogan, 1993), and
Foxc1 and Foxc2 regulate the specification of mesoderm to
paraxial versus intermediate fates (Wilm et al., 2004).Therefore, the two genes may normally repress expression of
VEGF in the paraxial mesoderm and somite as a feedback loop,
controlling the arterial identity of angioblasts derived from the
lateral mesoderm as proposed (Lawson and Weinstein, 2002).
Wild-type and compound homozygous embryos showed no
significant differences in the number and distribution of either
proliferating or apoptotic cells in endothelial cells as well as
other tissues in both the embryo proper and yolk sac (data not
shown). Given that endothelial cell proliferation in compound
homozygotes appeared normal despite the upregulation of
VEGF expression, one possibility is that the primary defect is a
failure of Foxc1/c2-null endothelial cells to respond to the
VEGF signal. As described below, the downregulation of
Neuropilin-1 expression also supports this idea. Another non-
mutually exclusive possibility is that the dysregulation of VEGF
expression in compound homozygotes may affect the precise
control of arterial specification of endothelial cells because the
definitive endoderm in mice is a potent source of VEGF
(Miquerol et al., 1999).
Recent studies indicate that VEGF-induced specific signal to
induce arterial specification is transmitted via the phospholipase
Cγ-1 (Lawson et al., 2003) or phosphatidylinositol 3-kinase/
Akt pathway (Liu et al., 2003), and that VEGF induces
expression of Notch1 and Dll4 in arterial endothelial cells (Liu
et al., 2003). However, transcription factors that act downstream
of the VEGF-induced arterial signal to regulate gene expression
have not been identified. Although the precise functional
interactions between Foxc and VEGF remain to be elucidated,
Foxc1 and Foxc2 may act as intracellular regulators down-
stream of VEGF signaling in arterial specification. Coupled
with evidence that Foxc1 and Foxc2 are phosphoproteins in
which a number of residues predicted to be phosphorylated
(Berry et al., 2002; H.F. and T.K., unpublished results), it is
plausible that precise transcriptional activity of Foxc proteins is
regulated by VEGF-mediated phosphorylation/dephosphoryla-
tion. These possibilities are now being investigated.
It is still not clear how VEGF can discriminate one type of
endothelial cell from another (e.g., a preference for arterial or
venous endothelial precursors). Because Neuropilin-1, a
coreceptor for VEGF receptors, is preferentially expressed in
arterial endothelial cells (Moyon et al., 2001), it is thought that
this coreceptor is a determinant for VEGF-mediated arterial
signal or possibly induced to enhance/maintain the expression
of artery-specific markers. This is consistent with our
observation that in compound homozygotes Neuropilin-1
expression was significantly reduced as early as E8.25 (Fig.
1P and data not shown). A recent study provides evidence that
COUP-TFII determines the venous cell fate by suppressing
expression of Neuropilin-1 and Notch signaling genes, whereas
COUP-TFII-mutant veins can acquire arterial characteristics
(You et al., 2005). By contrast, Dll4 mutant embryos exhibit the
ectopic expression of the venous marker EphB4 in the artery
(Duarte et al., 2004), consistent with those seen in compound
Foxc1; Foxc2 mutants (Fig. 2V). Together, these data suggest
that the precise control of the establishment and maintenance of
arterial-venous identity is a complex process that may be
regulated by counteraction between Foxc and COUP-TFII.
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mutants
Mutations of the human FOXC2 gene are associated with
dominantly inherited lymphedema (Fang et al., 2000). Foxc2
homozygous mutants have agenesis of lymphatic valves and
aberrant pericyte recruitment of lymphatic vessels (Petrova et
al., 2004), although they have been reported to be normal in
early lymphatic development. We show in this paper that
compound Foxc1+/−; Foxc2−/− mutant embryos exhibit a
reduced number of lymphatic endothelial cells sprouting from
the vein in the early stage of lymphatic development. Although
Foxc1 expression has been shown to be negative in lymphatic
vessels (Dagenais et al., 2004), Foxc1 and Foxc2 are
coexpressed in mesenchymal cells surrounding the cardinal
veins (Figs. 3F and G). Because these mesencymal cells alsoFig. 5.Dll4 is a direct downstream target of Foxc proteins. (A) Promoter regions of mu
with more than 90% identity. The HHR2 contains a consensus forkhead-binding elem
Both in vitro translated Foxc1 and Foxc2 proteins form DNA–protein complexes w
unlabeled oligonucleotides in a dose-dependent manner (lanes 4, 5, 7, and 8). No
pcDNA3.0 used as a control (Mock). (C) Luciferase reporter constructs. Note that th
Foxc1 and Foxc2 transactivate pDll4-3.7k-Luc in COS-7 cells in a dose-dependent
Foxc is significantly reduced. *Significantly different from control (pcDNA3.0), Pproduce VEGF-C, which is required for initial sprouting of
lymphatic endothelial cells (Karkkainen et al., 2004), the
lymphatic phenotype observed in compound Foxc mutants is
most likely attributed to the reduction of VEGF-C expression. It
is currently unclear whether Foxc proteins directly regulate
VEGF-C gene expression, and this possibility needs to be
investigated further. Thus, coupled with the previous studies
(Dagenais et al., 2004; Fang et al., 2000; Kriederman et al.,
2003; Petrova et al., 2004), our results indicate that the dosage
effects of Foxc1 and Foxc2 are involved in multiple processes
of lymphatic vascular development.
Foxc directly regulates Dll4 gene expression
One of the most important findings is that Foxc1 and Foxc2
directly activate Dll4 transcription via a Foxc-binding elementrineDll4 and humanDLL4. They share two highly homologous regions (HHRs)
ent (FBE) shown in bold. (B) Electrophoretic gel mobility shift assays (EMSA).
ith the FBE in the Dll4 promoter (lanes 3 and 6). The probes are competed by
DNA–protein complex (lane 2) is observed with the blank expression vector
e FBE in pDll4-3.7kmut-Luc is disrupted. (D) Luciferase reporter assays. Both
manner, while luciferase activity of pDll4-3.7kmut-Luc and pDll4-2.1k-Luc by
< 0.05.
Fig. 5 (continued).
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transcription factors identified to directly regulate Dll4
expression during vascular development. Although a single
Foxc-binding element is significantly important for the
induction of Dll4 expression, it is interesting that the mutation
of FBE is not completely able to attenuate Dll4 induction by
Foxc2. Given that combinatorial regulation of gene expression
by different classes of transcription factors is critical for
vascular development (Kappel et al., 2000; Minami et al., 2003;
Oettgen, 2001), other transcription factor(s), which binds to the
HHR1 and interacts with Foxc2, may be responsible for the total
regulation of Dll4 transcription. Interestingly, we found that the
HHR1 includes one putative biding site for the basic helix–
loop–helix transcription factor SCL/Tal-1, whereas there are
two SCL/Tal-1 binding sites and one Ets-binding site in the
HHR2 (data not shown).
It should be noted that inactivation of all four alleles for Foxc
result in more severe vascular defects than only two or three
alleles are absent in vivo. Because there are putative Foxc-
binding sites in conserved regions upstream of the 3.7 kb
promoter (data not shown), multiple binding elements for Foxcproteins may be essential for the full induction of Dll4
expression. In any case, it will be important to test the
significance of the newly-identified FBE in theDll4 promoter in
vivo using transgenic approaches, as in the case of a recently
identified target of Foxc, Tbx1, in the development of the
pharyngeal arches (Yamagishi et al., 2003). Such experiments
are underway to validate the direct regulation of Dll4 gene
expression by Foxc.
We found that Foxc2 can more strongly transactivate the
Dll4 promoter than Foxc1. Importantly, although some
compound Foxc1+/−; Foxc2−/− mutants exhibited AVMs as
those seen in compound homozygotes, compound Foxc1−/−;
Foxc2+/− mutants did form normal dorsal aortae and cardinal
veins (Fig. 1 and data not shown), suggesting that there are
some functional differences between the two genes. Although a
duplication of the ancestral Foxc gene is quite likely to occur in
the course of evolution (Carlsson and Mahlapuu, 2002), they
may develop independent roles during evolution. For example,
each single mutant dies with some distinct phenotypes (e.g.,
hydrocephalus in Foxc1−/−) (Kume et al., 1998). Thus, as
described above, we predict that Foxc1 and Foxc2 have mostly
468 S. Seo et al. / Developmental Biology 294 (2006) 458–470overlapping, but some distinct functions during vascular
development.
In addition to Dll4, transcripts of other arterial markers such
as Notch1/4 were reduced in endothelial cells of compound
homozygotes (Fig. 2), and expression of these genes was
significantly induced by Foxc in vitro (Fig. 4). It has been
shown that C.elegans Pha-4, a Foxa homologue, controls the
expression of many regulatory genes throughout pharynx
development (Gaudet and Mango, 2002), and that Foxo1
regulates many genes associated with vascular destabilization/
remodeling and endothelial cell apoptosis (Daly et al., 2004). A
recent study has demonstrated that the AP-1 transcription factor
controls the transcription of the human NOTCH4 gene in
vascular endothelial cells via an AP-1 binding site in its
promoter (Wu et al., 2005). Interestingly, we found that this AP-
1 binding site is adjacent to a putative Forkhead binding site
(data not shown). It is, therefore, tantalizing to speculate that
Foxc1 and Foxc2 also regulate expression of Notch4 in the
process of arterial specification.
In conclusion, our results suggest that the two Foxc genes
function together at an earlier stage to critically control the
proper process of arterial specification by regulating expression
of Notch signaling genes such as Dll4. In addition, while Foxc2
alone has been shown to play a role in late lymphatic
developmental processes such as the formation and mainte-
nance of the valves (Petrova et al., 2004), Foxc1 and Foxc2
cooperatively regulate sprouting of lymphatic endothelial cells.
Therefore, the phenotype of compound Foxc1; Foxc2 mutants
reported here provides new insights into the molecular
mechanisms underlying arterial specification and lymphatic
sprouting during early embryonic development.
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